Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,873 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04343573 | Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors | completed | Phase 2 | 102 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439172 | Pre-Radiation Chemotherapy for Newly Diagnosed High-Grade Glioma.(PRC) | not yet recruiting | Phase 2 | 70 | The Cooper Health SystemOTHER | 0 | Feb 27, 2026 |
| clinicaltrials |
| NCT01068782 | Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse | terminated | Phase 2 | 19 | ExelixisINDUSTRY | 2 | Feb 25, 2026 | clinicaltrials |
| NCT02125786 | A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma | active not recruiting | Phase 2 | 68 | St. Jude Children's Research HospitalOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT02942264 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | recruiting | Phase 1 / Phase 2 | 100 | Medical College of WisconsinOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT06058988 | Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer | recruiting | Phase 2 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04421560 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | recruiting | Phase 1 / Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05345002 | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | recruiting | Phase 2 | 55 | Stephen Bagley, MD, MSCEOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03794349 | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | active not recruiting | Phase 2 | 94 | Children's Oncology GroupNETWORK | 5 | Feb 18, 2026 | clinicaltrials |
| NCT07318818 | A Clinical Trial of P134 Cells in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 26 | Tasly Pharmaceutical Group Co., LtdINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07416890 | Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma | recruiting | Phase 2 | 24 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04765514 | Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients | recruiting | Phase 2 | 107 | AHS Cancer Control AlbertaOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07263438 | Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial(Phenix) | recruiting | Phase 2 | 59 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07410520 | PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. | recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03529448 | TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma(GEINOCANN) | completed | Phase 1 / Phase 2 | 33 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04711135 | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs(NETTER-P) | active not recruiting | Phase 2 | 11 | Advanced Accelerator ApplicationsINDUSTRY | 5 | Feb 12, 2026 | clinicaltrials |
| NCT07405255 | Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma(Zillion) | not yet recruiting | Phase 2 | 19 | Ruijin HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | withdrawn | Phase 2 | 0 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06132685 | Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial | recruiting | Phase 2 | 200 | Emory UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07399821 | An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma(GLOW-FISH) | recruiting | Phase 1 / Phase 2 | 22 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03581942 | Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) | completed | Phase 1 / Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT03405792 | Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)(2-THE-TOP) | active not recruiting | Phase 2 | 40 | University of FloridaOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04872543 | A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | recruiting | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05700721 | Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET) | recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours(5G-PEARL) | recruiting | Phase 1 / Phase 2 | 64 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05653622 | Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma(SIB-DOPA) | recruiting | Phase 2 | 75 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05653635 | Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study(ReciDOPA) | recruiting | Phase 2 | 54 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02315326 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | completed | Phase 1 / Phase 2 | 93 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT04187404 | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma(Spencer) | terminated | Phase 1 / Phase 2 | 70 | EnteromeINDUSTRY | 8 | Jan 30, 2026 | clinicaltrials |
| NCT05683808 | Venous Thromboembolism Prevention in Outpatients With Glioma(VTE-POG) | recruiting | Phase 2 | 40 | University of Vermont Medical CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT04401774 | Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04752813 | A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | active not recruiting | Phase 2 | 50 | BPGbioINDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT06012929 | A Study of ONC201 for Refractory Meningioma | withdrawn | Phase 2 | 0 | University of NebraskaOTHER | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07365280 | Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 78 | ZSky Biotech IncINDUSTRY | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07365410 | Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | not yet recruiting | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07364786 | Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma(AFGBMBiop) | recruiting | Phase 2 | 10 | Peter SiesjöOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | recruiting | Phase 1 / Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours(5G-RUBY) | recruiting | Phase 1 / Phase 2 | 182 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06907485 | A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients | not yet recruiting | Phase 2 | 20 | Costas HadjipanayisOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT06105619 | A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). | active not recruiting | Phase 2 / Phase 3 | 84 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07347210 | Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma(MATVAC-1) | not yet recruiting | Phase 2 | 98 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 16, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2026source: clinicaltrials